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Abstract 
Objective: Growing evidence suggested an association between aortic valve sclerosis (AVSc) and 
cardiovascular (CV) events. However, little is known about the association of AVSc with major 
markers of subclinical atherosclerosis. We performed a meta-analysis of literature studies to address 
this issue. 
Approach and Results: Studies on the relationship between AVSc and common carotid artery 
intima-media thickness (IMT), prevalence of carotid plaques (CPs), flow-mediated dilation (FMD), 
aortic pulse wave velocity (PWV) and augmentation index (AIx) were systematically searched in 
electronic databases. Thirteen studies enrolling 1086 AVSc patients and 2124 controls were 
included. Compared to controls, AVSc patients showed higher IMT (MD: 0.32 mm; 95%CI: 0.07, 
0.58; p=0.014), and higher prevalence of CPs (OR: 4.06; 95%CI: 2.38, 6.93; p<0.001). Moreover, 
lower FMD (MD: -4.48%; 95%CI: -7.23, -1.74; p=0.001) and higher PWV (MD: 0.96%; 95%CI: 
0.11, 1.81; p=0.027) were found in AVSc subjects than in controls, with no differences in AIx (MD: 
0.76%; 95%CI: -0.97, 2.49; p=0.389). In Meta-regression analyses body mass index and 
triglycerides levels have an impact on the difference in IMT between cases and controls, while male 
gender and smoking habit were associated with the difference in the prevalence of CPs between the 
two groups.  
Conclusion: AVSc is significantly associated with altered markers of subclinical atherosclerosis, 
thus supporting the concept that AVSc and atherosclerosis share common etiopathological 
mechanism and/or risk factors. On this basis, an echocardiogram carried out to assess the state of 
the aortic valve would be desirable whenever an altered subclinical marker of atherosclerosis is 
found. 
 
Keywords  
Aortic valve sclerosis, subclinical atherosclerosis, intima-media thickness, carotid plaques, 
endothelial function, arterial stiffness. 
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Introduction 
Aortic valve sclerosis (AVSc) has become, in the last decade, very popular among clinicians and 
scientists. This interest is due to the strong correlation that this condition has with aortic valve 
stenosis, coronary artery events, stroke, cardiovascular mortality and all-cause mortality[1]. 
AVSc is generally characterized by focal or diffuse aortic valve thickening with or without 
increased echogenicity and without any significant hemodynamic effects[2]. AVSc is identified by 
EAE/ASE and AHA/ACC guidelines as unrestricted leaflet opening with a maximal transvalvular 
velocity of <2.0 m/s[3] and < 2.5 m/s[4] on Doppler echocardiographic measurement, respectively. 
The prevalence of this condition is estimated around 30% in patients older than 65 years and up to 
40% in those older than 75 years[2]. In addition, a strong correlation between AVSc and 
conventional vascular risk factors (VRFs) has been reported in several studies[5-7]. In particular, 
the association with age, male gender, hypertension, hyperlipidemia, diabetes and smoking suggests 
that AVSc might be considered an atherosclerosis-like process[2, 7]. A recent study by Coffey et 
al.[1] has reported that AVSc patients have a low rate of progression (≈ 2% every year) to 
symptomatic aortic valve stenosis. In spite of the dramatic increase in the literature of the field, 
whether AVSc is just a marker of valve degeneration rather than a generalized vascular disease is 
still matter of debate[1]. 
The recent advancement of imaging modalities has made possible the non-invasive assessment of a 
number of morphological and functional aspects of atherosclerosis disease, in all phases of its 
development. Carotid intima-media thickness (cIMT), carotid plaques (CPs), flow-mediated dilation 
(FMD), aortic pulse wave velocity (PWV) and aortic augmentation index (AIx) are all examples of 
these non-invasive arterial morphology or functional modalities. Convincing evidence are now 
available showing that each one of these variables is able to add prognostic information over and 
above conventional VRFs and all are independent predictors of CV events[8-14]. For these reason 
all these variables are now widely accepted as surrogate markers of subclinical and even clinical 
atherosclerosis. During recent years, a series of single studies have investigated the association 
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between AVSc and these markers of atherosclerosis proving accelerated atherosclerosis[15], 
impaired endothelial function[16, 17], and increased arterial stiffness[18] in patients with aortic 
valve sclerosis. However, no one has addressed this issue by using a meta-analytic approach.   
To provide a comprehensive overview of these relationships, we performed a systematic review 
with meta-analysis of literature studies to evaluate the association of aortic valve sclerosis and 
major markers of subclinical atherosclerosis.  
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Methods 
A protocol for this review was prospectively developed, detailing the specific objectives, the criteria 
for study selection, the approach to assess study quality, the outcomes, and the statistical methods. 
 
Search strategy 
To identify all available studies, a detailed search pertaining to aortic valve sclerosis and markers of 
CV risk (i.e. IMT, FMD, NMD, PWV, AIx) was conducted according to Preferred Reporting Items 
for Systematic reviews and Meta-Analyses (PRISMA ) guidelines[19]. A systematic search was 
performed in the electronic databases (PubMed, Web of Science, Scopus, EMBASE), using the 
following search terms in all possible combinations: aortic valve sclerosis, intima-media thickness, 
carotid plaques, atherosclerosis, flow-mediated dilation, nitrate-mediated dilation, endothelium-
dependent dilation, endothelium-independent dilation, endothelial dysfunction, pulse wave velocity, 
augmentation index, arterial stiffness. The last search was performed on December 2015. The 
search strategy was developed without any language or publication year restriction.  
The reference lists of all retrieved articles were manually reviewed. In case of missing data, study 
authors were contacted by e-mail to try to retrieve original data. Two independent Authors 
(MNDDM and ADM) analyzed each article and performed the data extraction independently. In 
case of disagreement, a third investigator was consulted (PP). Discrepancies were resolved by 
consensus. Selection results showed a high inter-reader agreement (κ = 0.97) and have been 
reported according to PRISMA flowchart (Supplemental Figure 1). 
 
Data extraction and quality assessment 
According to the pre-specified protocol, all studies evaluating the impact of aortic valve sclerosis on 
the markers of CV risk were included. Case-reports, case-series without a control group, reviews 
and animal studies were excluded. To be included in the analysis, a study had to provide values 
(means with standard deviation) of at least one variable among the following: common carotid 
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artery IMT (IMT), brachial artery FMD, carotid-femoral PWV, aortic AIx. Studies reporting the 
prevalence of CPs were also included. We included only studies defining aortic valve sclerosis as 
focal or diffuse leaflet thickening with or without calcification, with normal valve excursion, and 
peak Doppler flow velocity of < 2.0 m/s[3, 4, 20]. In each study, data regarding sample size, major 
clinical and demographic variables, values of IMT, FMD, PWV and AIx and prevalence of CPs in 
patients with AVSc and healthy controls were extracted. 
Formal quality score adjudication was not used, since previous investigations failed to demonstrate 
its usefulness.[21] 
 
Statistical analysis and risk of bias assessment 
Statistical analysis was carried out using Comprehensive Meta-analysis [Version 2, Biostat, 
Englewood NJ (2005)].  
Differences among cases and controls were expressed as mean difference (MD) with pertinent 95% 
confidence intervals (95%CI) for continuous variables, and as Odds Ratio (OR) with pertinent 95% 
CI for dichotomous variables.  
IMT has been expressed in millimeters (mm), FMD and AIx as percentage (%), and PWV as mm 
per second (mm/s).  
The overall effect was tested using Z scores and significance was set at P <0.05. Statistical 
heterogeneity between studies was assessed with chi square cochran’s Q test and with I2 statistic, 
which measures the inconsistency across study results and describes the proportion of total variation 
in study estimates that is due to heterogeneity rather than sampling error. In detail, I
2
 values of 0% 
indicates no heterogeneity, 25% low, 25-50% moderate, and 50% high heterogeneity[22]. 
Publication bias was assessed by the Egger’s test and represented graphically by funnel plots of the 
standard difference in means versus the standard error. Visual inspection of funnel plot asymmetry 
was performed to address for possible small-study effect, and Egger’s test was used to assess 
publication bias, over and above any subjective evaluation. A p < 0.10 was considered statistically 
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significant[23]. In case of a significant publication bias, the Duval and Tweedie’s trim and fill 
method was used to allow for the estimation of an adjusted effect size[24]. In order to be as 
conservative as possible, the random-effect method was used for all analyses to take into account 
the variability among included studies. 
 
Meta regression analyses 
Differences among included studies may be affected by demographic variables (age, male gender) 
and traditional CV risk factors (hypertension, smoking habit, diabetes mellitus, obesity). To assess 
the possible effect of such variables in explaining different results observed across studies, we 
performed meta-regression analyses after implementing a regression model with difference in IMT, 
FMD, PWV, AIx values, or presence of CPs as dependent variables and the above mentioned 
covariates as independent variables. This analysis was performed with Comprehensive Meta-
analysis [Version 2, Biostat, Englewood NJ (2005)].  
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Results 
Study characteristics 
After excluding duplicate results, the search retrieved 176 articles. Of these, 160 were excluded 
because they were off the topic after scanning the title and/or the abstract or because they were 
reviews, comments, case reports or because they lacked of data of interest. Three studies were 
excluded after full-length paper evaluation.  
Thus, 13 studies on 1086 AVSc patients and 2124 controls were included in the final analysis 
(Supplemental Figure 1).  
Major characteristics of included studies are shown in Table 1. All studies had a cross-sectional 
design. The number of patients varied from 41 to 1065, the mean age from 44.3 to 72 years, and the 
prevalence of male gender from 29.3 to 74.5%. The presence of hypertension was reported in 34.5 - 
85.0% of patients, smoking habit in 6.3 - 50% and diabetes mellitus in 10.7 - 36.6%. Mean body 
mass index (BMI) varied from 22.1 to 32.0 Kg/m
2
.  
 
Common carotid artery intima media thickness (IMT) and carotid plaques (CPs) 
In 4 studies[16, 25-27],
 
we found a significantly higher IMT in 151 AVSc patients as compared to 
404 controls (mean difference - MD: 0.325 mm; 95%CI: 0.067, 0.582; P =0.014, Figure 1 panel 
A). The heterogeneity among studies was significant (I
2
 = 95.9%; p < 0.0001) but, after excluding 
one study at a time, we found that all the results were confirmed (data not shown). Also after 
excluding the study of Yamaura et al.[27], that reported the highest MD between AVSc patients and 
controls, the difference in IMT remained significant without heterogeneity (MD: 0.17 mm; 95%CI: 
0.13, 0.21; p < 0.0001, I
2
 = 0%; p = 0.48). Five studies[15, 16, 28-30],
 
showed an increased 
prevalence of CPs in 941 AVSc patients as compared to 1103 controls, with an OR of 4.06 (95%CI: 
2.38, 6.93; p < 0.001, Figure 1 panel B). The heterogeneity among studies was significant (I
2
 = 
65.3%; p = 0.021). Also, in this case, after excluding one study at a time, we found that all the 
results were confirmed (data not shown). In addition, after excluding the study of Schonenberger et 
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al.[29], that reported the highest OR between AVSc patients and controls, the same difference in the 
prevalence of carotid plaque was confirmed (OR: 3.62; 95%CI: 2.18, 6.01; p < 0.001, I
2
 = 64.8%; p 
= 0.036). Also excluding studies[16, 27] in which cases and controls were not age-matched, both 
the difference in IMT and in CPs prevalence were confirmed (MD: 0.18 mm; 95%CI: 0.11, 0.26; p 
< 0.001, I
2 
= 27.5%; p = 0.24 and OR: 3.98; 95%CI: 2.10, 7.55; p < 0.001, I
2 
= 73.2%; p = 0.011). 
 
Flow-Mediated Dilation (FMD)  
Two studies[16, 17],
 
evaluating a total of 63 cases and 146 controls, showed a significantly lower 
FMD in AVSc patients as compared to controls (MD: -4.48; 95%CI: -7.23, -1.74; p = 0.001, Figure 
2) with a significant heterogeneity among studies (I
2
 = 73.7%; p = 0.0051).  
 
Pulse wave velocity (PWV)  
Four studies[16, 18, 25, 31] showed a significantly higher PWV in the 230 AVSc patients as 
compared to 297 controls (MD: 0.96; 95%CI: 0.110, 1.81; p = 0.027, Figure 3 panel A). A 
significant heterogeneity among studies was found (I
2
 = 66.6%; p = 0.03). After excluding one 
study[31], that reported the highest MD between AVSc patients and controls, the significant 
difference in PWV values was confirmed without heterogeneity (MD: 0.60 mm; 95%CI: 0.00, 1.20; 
p = 0.05, I
2
 = 0%; p = 0.60). 
 
Augmentation Index (AIx)  
Five studies[16, 18, 25, 32, 33] evaluating a total of 214 cases and 485 controls, showed similar AIx 
values in AVSc patients and controls (MD: 0.76; 95%CI: -0.97, 2.49; p = 0.389, Figure 3 panel B) 
without heterogeneity among studies (I
2
 = 25.9%; p = 0.249). Of interest, after excluding the study 
by Erdogan et al.[16], that enrolled non aged-matched cohorts, the lack of difference in AIx values 
between AVSc patients and controls was consistently confirmed (MD: 0.99 mm; 95%CI: -1.07, 
3.06; p = 0.347, I
2
 = 41,5%; p = 0.162). 
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Publication bias 
Funnel plots of effect size versus standard error for studies evaluating IMT, CPs, PWV and AIx 
were rather symmetrical and the Egger’s test showed the absence of publication bias (Egger’s p = 
0.541; p = 0.500; p = 0.147 and p = 0.521, respectively, Supplemental Figure 2). 
 
Meta-regression analyses 
Regression models (Figure 4) showed that BMI and triglycerides levels significantly impacted on 
the difference in IMT between AVSc patients and controls (Z= -7.99, p < 0.001 and Z = -11.85, p < 
0.001, respectively), while male gender and smoking habit impacted on the difference in the 
prevalence of CPs (Z = -2.08, p = 0.037 and Z = 2.14, p = 0.032, Figure 5). All the other covariates 
(see methods section) did not impact on any subclinical atherosclerosis marker considered. 
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Discussion 
Results of the present meta-analysis consistently show that AVSc is associated with an increased 
carotid IMT, with a high prevalence of CPs, with an impaired flow-mediated dilation (FMD) and 
with a high pulse wave velocity (PWV). Our findings are strengthened by sensitivity analyses, 
which consistently confirm results of primary analyses. Regression models were used to further 
refine results, suggesting major clinical variables potentially impacting on the difference in carotid 
IMT and in the prevalence of CPs between AVSc patients and controls. Overall, these data clearly 
suggest that patients with an increased CV risk due to the presence of signs of subclinical 
atherosclerosis deserve to be evaluated for the presence of AVSc, which, in turn, may be considered 
as an additional CV risk factor. Accordingly, previous published studies reported an increased risk 
of major CV events and CV death in patients with AVSc[1]. 
In order to provide a comprehensive overview of the relationship between AVSc and subclinical 
atherosclerosis, in the present meta-analysis, which includes more than 2800 subjects, all the major 
recognized markers of CV risk were taken into account.  
Both, IMT and CPs, are recognized marker of subclinical atherosclerosis strongly associated with 
and increased CV risk[34]. A significantly decreased FMD and an increased PWV were found in 
AVSc patients[17]. The association between AVSc and Aix, the only indirect atherosclerosis 
marker took into account, showed a positive but not significant trend. The lack of significance could 
be explained by the method used to calculate this index, being AIx just an indirect measure of aortic 
arterial stiffness. In addition, a series of CV risk factors, particularly aging, are known to impact this 
variable[35]. The lack of difference in AIx values between AVSc patients and controls was 
consistently confirmed also after specifically analysing studies enrolling age-matched cohorts. 
To strengthen our results, it would have been useful to assess also the prevalence of CV events 
among AVSc subjects and healthy controls. Unfortunately, this has not been possible because most 
of the studies considered have specifically excluded patients with clinically proven coronary artery 
disease, history of myocardial infarction and/or cerebrovascular accidents. 
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Overall, patients with AVSc have an increased likelihood to present signs of subclinical 
atherosclerosis and the clinical relevance of our results becomes evident considering that the risk of 
myocardial infarction increases of 43% every 0.163 mm increase in carotid IMT[36]. An even 
better predictor of CV events than IMT is represented by the prevalence of CPs[34, 37]. In addition, 
our results on FMD further confirm the presence of accelerated atherosclerosis in patients with 
AVSc. The rationale for the association between FMD and CV prognosis is the assumption that 
FMD reflects endothelium-dependent dilation and, in turn, nitric oxide (NO) bioavailability[38]. 
Endothelium-derived NO possesses several anti-atherogenic and plaque stabilizing properties, 
including inhibition of cell growth and proliferation, regulation of vascular tone and arterial wall 
stress, inhibition of leukocyte and platelet adhesion, and antithrombotic and fibrinolytic 
properties[37]. In keeping with this, it has been documented that each 1% decrease in FMD is 
associated with a 12% increase of CV events[39]. Furthermore, we have to consider that the risk of 
major CV events increases of about 14% each 1 m/s increase in PWV[40].  
In our meta-regression analysis BMI and triglycerides levels impacted positively on the difference 
in IMT between AVSc patients and controls, whereas male gender impacted inversely on the 
difference in the prevalence of CPs between the two groups. These results can be due to  the direct 
pro-atherogenic effects of obesity, hypertriglyceridemia and male gender. On the other hand, the 
fact that the associations observed remain significant also after adjustment for these covariates 
suggests that, in the presence of AVSc, sub-clinical atherosclerosis can be found also in patients 
without these CV risk factors. Whether the concomitant presence of AVSc and markers of 
subclinical atherosclerosis, may add in risk stratification over and above the possible common 
effects of conventional VRFs and whether a preventive strategy may be useful also for the control 
of AVSc progression remains to be established. Furthers ad hoc studies specifically designed to 
better understand the meaning of these associations are needed. 
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Some potential limitations of our study need to be discussed. First, the studies included in our meta-
analysis have different inclusion and exclusion criteria and patients included had concomitant CV 
risk factors (hypertension, smoking, obesity, diabetes mellitus, and hyperlipidemia). With the meta-
regression approach, we have attempt to address this issue but data available have allowed to adjust 
the analyses for some, but not all the potential confounders. Second, heterogeneity among the 
studies was generally significant. However, all results have been confirmed without heterogeneity 
after the exclusion of one study at a time or excluding studies enrolling non age-matched patients. 
Thus, although unable to conclusively ascertain all potential sources of heterogeneity, we are 
confident that its impact on results can be considered almost negligible. The last potential study 
limitation lies in the definition of CPs, which widely varied among studies considered. Despite this, 
the association with AVSc was consistently confirmed for all evaluated outcomes.  
 
In conclusion, our meta-analysis shows that AVSc is significantly associated with subclinical 
atherosclerosis and endothelial dysfunction. These results strongly suggest that valve degeneration 
and atherosclerosis might share some etiopathological mechanisms and/or predisposing factors. On 
this basis, an echocardiographic assessment the aortic valve status would be desirable whenever an 
altered marker of subclinical atherosclerosis is found.  
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Highlights 
 
- Aortic valve sclerosis (AVSc) is correlated with classical risk factors for cardiovascular 
disease and it is considered an atherosclerosis-like process.  
 
- The association of AVSc with markers of cardiovascular risk is poorly studied and widely 
discussed. 
 
- We found that AVSc is associated with an increased subclinical atherosclerosis and with 
impaired endothelial function; all being recognized as major predictors of cardiovascular 
risk. 
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Table 1. Demographic and clinical data of patients with aortic valve sclerosis and controls in included studies. 
Author 
Patients 
(n) 
Males 
(%) 
Age  
(years) 
HT  
(%) 
Smoking  
(%) 
DM 
(%) 
BMI 
(kg/m
2
) 
TC 
(mg/dl) 
LDLc 
(mg/dl) 
HDLc 
(mg/dl) 
TGs 
(mg/dl) 
*Antonini-Canterin  
2009[15] 
AVSc 70 - - - - - - - - - - 
Controls 409 - - - - - - - - - - 
Celik  
2008[18] 
AVSc 62 77 65 63 29 18 29 180 118 52 134 
Controls 62 42 63 60 26 16 30 195 125 50 162 
Erdogan  
2013[16] 
AVSc 28 71 57 - 68 - 32 230 136 45 187 
Controls 79 46 47 - 39 - 32 219 146 49 168 
Korkmaz  
2013[25] 
AVSc 60 73 67 52 18 23 30 193 126 39 177 
Controls 76 67 66 50 12 21 30 186 128 37 158 
Korkmaz  
2013_2[31] 
AVSc 80 41 73 89 16 14 29 205 137 43 149 
Controls 80 35 71 81 14 16 31 208 139 47 148 
Ngo  
2009[32] 
AVSc 49 49 65 33 12 10 27 - - - - 
Controls 204 42 63 44 15 11 29 - - - - 
Nightingale  
2011[33] 
AVSc 15 47 69 - 7 - 24 201 - - - 
Controls 64 55 67 - 6 - 27 201 - - - 
Poggianti  
2003[17] 
AVSc 35 74 64 40 46 17 27 221 124 - 170 
Controls 67 75 63 55 52 16 27 200 133 - 178 
*Rossi  
2014[28] 
AVSc 423 - - - - - - - - - - 
Controls 642 - - - - - - - - - - 
Schönenberger  
2004[29] 
AVSc 19 - 64 - - 42 - - - - - 
Controls 22 - 52 - - 32 - - - - - 
Sgorbini  
2007[26] 
AVSc 36 33 68 - 19 - 30 205 127 48 149 
Controls 24 33 68 - 33 - 28 215 136 48 149 
Soylu 
2003[30] 
AVSc 182 61 62 36 25 15 - - - - - 
Controls 170 60 64 33 25 11 - - - - - 
Yamaura  
2004[27] 
AVSc 27 59 55 - 52 - 23 217 129 68 101 
Controls 225 45 43 - 26 - 22 198 114 64 82 
AVSc: aortic valve sclerosis; HT: hypertension; DM: diabetes mellitus; BMI: body mass index; TC: Total Cholesterol; LDLc: LDL-cholesterol; 
HDLc: HDL-cholesterol; TGs: triglycerides.  
*Studies not reporting clinical and demographic data stratified according to the presence of aortic valve sclerosis. 
Age, BMI, TC, LDLc, HDLc, and TGs are expressed as mean values.
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Figure Legends 
 
Figure 1. Common carotid artery intima-media thickness (Panel A) and prevalence of carotid 
plaques (Panel B) in aortic valve sclerosis (AVSc) patients and controls. 
 
Figure 2. Flow mediated-dilation (FMD) in aortic valve sclerosis (AVSc) patients and controls. 
 
Figure 3. Pulse wave velocity (Panel A) and Augmentation index (Panel B) in aortic valve 
sclerosis (AVSc) patients and controls. 
 
Figure 4. Meta-regression analysis. Effect of body mass index (BMI) and triglycerides levels 
on the difference in carotid intima-media thickness between aortic valve sclerosis (AVSc) 
patients and controls. 
 
Figure 5. Meta-regression analysis. Effect of prevalence of male gender and smoking habit on 
the difference in carotid intima-media thickness between aortic valve sclerosis (AVSc) 
patients and controls. 
 
 




On-line supplemental material 
Supplemental Figure 1. Prisma Flow Diagram 
 
  
Supplemental Figure 2. Funnel plots of effect size versus standard error for studies evaluating 
common carotid artery intima-media thickness, carotid plaques, pulse wave velocity and 
augmentation index in aortic valve sclerosis (AVSc) patients and controls.  
 
 
 
 
 
 
Note: Funnel plots of effect size versus standard error for studies evaluating flow mediated 
dilation in aortic valve sclerosis (AVSc) patients and controls was not produced because less 
than 3 studies evaluated this outcome.  
